These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26381901)

  • 1. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
    Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
    Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.
    De Miguel D; Gallego-Lleyda A; Ayuso JM; Pejenaute-Ochoa D; Jarauta V; Marzo I; Fernández LJ; Ochoa I; Conde B; Anel A; Martinez-Lostao L
    Cancer Lett; 2016 Dec; 383(2):250-260. PubMed ID: 27725224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
    Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
    Qiao X; Wang X; Shang Y; Li Y; Chen SZ
    Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X
    Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
    Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
    Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation.
    Chen L; Hao M; Yan J; Sun L; Tai G; Cheng H; Zhou Y
    J Biol Chem; 2021; 296():100515. PubMed ID: 33676890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icariin sensitizes human colon cancer cells to TRAIL‑induced apoptosis via ERK‑mediated upregulation of death receptors.
    Kim B; Seo JH; Lee KY; Park B
    Int J Oncol; 2020 Mar; 56(3):821-834. PubMed ID: 32124960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
    Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
    Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.
    Kim TH; Jo YG; Jiang HH; Lim SM; Youn YS; Lee S; Chen X; Byun Y; Lee KC
    J Control Release; 2012 Sep; 162(2):422-8. PubMed ID: 22824780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.